Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cigna Retains Formulary Management Control Under Contract With PBM Catamaran

This article was originally published in The Pink Sheet Daily

Executive Summary

Under the 10-year contract, Catamaran will bring its “leading technology and service platform” to enhance operations of Cigna’s internal PBM. The deal is also expected to bolster Cigna’s drug purchasing power and help lower costs.

You may also be interested in...



Express Scripts Combination With Cigna's PBM Could Reverse Deficit From Losing Anthem

Merger could restore number of covered lives PBM will lose once its contract with Anthem expires, but there is also risk of alienating current health plan clients who don't want to contract with a competitor.

Deal Watch: Teva Boosts CNS Portfolio With $3.2 Billion Purchase Of Auspex

Novartis raises its game in immuno-oncology through Aduro collaboration, while Merck Serono partners up with a CAR-T program at Intrexon. UnitedHealth grows its PBM business by acquiring Catamaran; Horizon expands its orphan drug portfolio in buyout of Hyperion.

OptumRx To Be ‘Competitive Force’ In PBM Industry With Catamaran Buy

The merger of UnitedHealth Group’s pharmacy benefit manager OptumRx with Catamaran could give the combined firm greater pricing leverage as it becomes one of the industry's giants, along with CVS Health’s Caremark and Express Scripts.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS075823

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel